HYRNUO TARGETS AND BLOCKS HER2 MUTATIONS
HYRNUO works by targeting receptors on cells that signal growth, including cancer cells with mutated HER2.† These mutations can lead to signals that promote uncontrolled and rapid growth of cancer cells. HYRNUO is designed to block these signals, which may help slow or stop the growth of cancer cells.
HYRNUO is not chemotherapy, it is a treatment called a tyrosine kinase inhibitor (TKI).‡
†A mutation is an abnormal change in a gene. The gene is the basic unit of heredity passed down from parent to child. Genes are made up of DNA.
‡A TKI is a targeted therapy that inhibits cancer cell growth.
DNA=deoxyribonucleic acid.